Funding for medical research
21 February, 2014The latest NHMRC funding round will see $133 million allocated to grant support for medical research.
Potential new approach to treating melanoma
21 February, 2014 by Susan WilliamsonBlocking the delivery of amino acids to melanoma cells may provide another way of tackling this difficult-to-treat disease.
Sirtex 1H14 profit grows 45%
18 February, 2014 by Dylan Bushell-EmblingHigher-dose sales of Sirtex Medical's (ASX:SRX) SIR-Spheres liver cancer treatments and a weaker Australian dollar helped the company grow its revenue and profit for the first half of FY14.
Australian medical research measures up
18 February, 2014The NHMRC's recently released bibliometric report reveals a strong international position for Australian health and medical research.
Biotron granted US patent for BIT225
14 February, 2014 by Dylan Bushell-EmblingBiotron (ASX:BIT) has secured patent protection in the US for BIT225, its antiviral compound under development as a treatment for HIV and HCV.
Patrys improves cash position in 1H14
13 February, 2014 by Dylan Bushell-EmblingPatrys's (ASX:PAB) recent capital raising has left it in its strongest cash position since 2008 and given it adequate funding to advance its clinical trial programs, according to its 1H14 report.
Analytica promotes COO Geoff Daly to CEO
13 February, 2014 by Dylan Bushell-EmblingAnalytica (ASX:ALT) COO Geoff Daly will step up to CEO as the company gears up for the planned launch of urinary incontinence treatment device PeriCoach.
Alchemia names new chairman
11 February, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has selected a permanent successor to the post of chairman, following the retirement of long-serving chair Mel Bridges last year.
Nanoplastic catches cancer cells
07 February, 2014A simple method for capturing cancer cells in the blood could improve patient prognosis and response to treatment.
Million-dollar grant to roll out HIV test
07 February, 2014An easy-to-use HIV diagnostic has received funding of US$1.6 million to kickstart field studies.
Prima wins more approvals for ovarian cancer trial
06 February, 2014 by Dylan Bushell-EmblingRegulatory agencies from Latvia, Lithuania, Ukraine and Belarus have joined their Belgian counterpart in signing off on Prima BioMed's (ASX:PRR) CAN-004 trial.
Viralytics to get new US oncolytic virus patent
06 February, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) has been granted a notice of allowance for a US patent covering anticancer candidate Cavatak and the family of oncolytic viruses to which it belongs.
Promising results from ovarian cancer trial: Bionomics
03 February, 2014 by Dylan Bushell-EmblingBionomics' BNC105 has so far shown signs of triggering a positive response in 10 of the 15 patients treated in the first stage of a phase I/II trial.
Neuren on track with "watershed" clinical trials
30 January, 2014 by Dylan Bushell-EmblingNeuren (ASX:NEU) is well underway with clinical trials of drug candidate NNZ-2566 in neurological conditions including Fragile X syndrome, Rett syndrome and traumatic brain injury.
Drawbridge wins patents for anaesthesia candidate
30 January, 2014 by Dylan Bushell-EmblingDrawbridge Pharmaceuticals has picked up patents in six countries for Phaxan, its anaesthesia drug candidate that entered the phase IC trial stage this month.
